U.S. Semiconductors Stock News

Wondering if UnitedHealth Group is now quietly turning into a value opportunity after a rough stretch in the market? This article will walk through whether the current price actually makes sense. Despite a modest 1.1% gain over the last 7 days and 0.8% over the past month, the stock is still down 33.9% year to date and 41.2% over the last year, with only a 5.8% gain over 5 years. Recent headlines have centered on regulatory scrutiny of managed care, shifting dynamics in Medicare Advantage,...

With a price-to-earnings (or "P/E") ratio of 42x Zurn Elkay Water Solutions Corporation ( NYSE:ZWS ) may be sending...

The board of The Campbell's Company ( NASDAQ:CPB ) has announced that it will pay a dividend of $0.39 per share on the...

The IREN Limited ( NASDAQ:IREN ) share price has softened a substantial 30% over the previous 30 days, handing back...

Humana Inc.'s ( NYSE:HUM ) investors are due to receive a payment of $0.885 per share on 30th of January. This payment...

Marvell Technology (MRVL) just delivered a record third quarter and quietly tightened its grip on cloud security, pairing strong earnings with a deeper Microsoft Azure partnership across newly certified European markets. See our latest analysis for Marvell Technology. Those blockbuster earnings, the Celestial AI deal and the Azure expansion have all fed into a sharp re-rating, with a 90 day share price return of 55.05% contrasting with a 3 year total shareholder return of 139.44%. This...

SS Innovations International (SSII) is catching investor attention as demand accelerates for its SSi Mantra 3 surgical robotic system, with rising installations and procedure volumes underscoring the platform’s growing adoption in cost sensitive healthcare markets. See our latest analysis for SS Innovations International. Despite the recent pullback, with a 30 day share price return of minus 15.75 percent at 6.34 dollars and a year to date share price return of minus 18.72 percent, the 1 year...

Rapport Therapeutics (RAPP) is stepping into a key spotlight, with plans to unveil detailed Phase 2a data for its lead epilepsy candidate RAP-219 at the 2025 American Epilepsy Society meeting in Atlanta. See our latest analysis for Rapport Therapeutics. The upcoming AES presentation lands after a powerful run, with the share price at $28.70 and a 90 day share price return of nearly 100 percent, suggesting momentum has been building as investors reassess RAP 219’s potential. If this kind of...

Delek US Holdings (DK) has quietly delivered a strong run over the past year, even as revenue slipped and net income stayed negative. This raises a straightforward question for investors: Is this momentum sustainable or stretched? See our latest analysis for Delek US Holdings. The recent pullback, with a 7 day share price return of negative 3.19 percent after a powerful year to date share price return of 104.07 percent, suggests momentum is pausing rather than breaking as investors reassess...

Kinetik Holdings (KNTK) is back in focus after disappointing third quarter 2025 results led management to cut 2025 EBITDA guidance, citing operational hiccups and delays at the key Kings Landing project. See our latest analysis for Kinetik Holdings. The guidance cut helps explain why Kinetik’s 1 year total shareholder return is down sharply. The stock has bounced with a 7 day share price return of 9.27 percent, suggesting near term sentiment is stabilising but longer term momentum has...

Recently, NNN REIT Inc reported that short interest rose by 8.54% since the prior update, with 5.44 million shares sold short, equal to 3.94% of its freely tradable shares. Even after this increase, NNN REIT’s short interest remains lower than that of many retail REIT peers, highlighting a relatively more constructive positioning by bearish investors. We’ll now explore how the recent rise in short interest could influence NNN REIT’s investment narrative built on resilient, necessity-based...

Main Street Capital (MAIN) just committed another $20 million in first lien, senior secured term debt to portfolio company Chamberlin Holding, backing its latest acquisition and geographic expansion while underscoring management’s confidence in the investment pipeline. See our latest analysis for Main Street Capital. That steady deployment of first lien capital comes after a modest Q3 earnings miss, yet Main Street’s roughly 5 percent 1 month share price return and robust multi year total...

Papa Johns and franchise partner Pie Investments recently refranchised 85 company-linked restaurants in the Washington, D.C. and Baltimore areas and outlined plans to open 52 additional locations across Greater Philadelphia, Washington, D.C. and Baltimore by 2030, consolidating these key markets under one of its largest U.S. franchise operators. This handover from long-time franchisee William Freitas’ joint venture to Chris Patel’s Pie Investments marks a meaningful shift in Papa Johns’ East...

Banc of California recently reached a 52-week high while management increased share repurchases and declared a quarterly cash dividend on both common and preferred stock, reinforcing its current capital return approach. Together, these actions point to management’s conviction in the bank’s balance sheet strength and earnings power, which many investors watch as a signal of confidence. Now we’ll examine how the stepped-up share repurchases intersect with Banc of California’s existing...

In recent months, TPG Capital has backed a TCS-led US$2.00 billion AI data center joint venture in India and, through a consortium with MAVCO, completed the acquisition of Siemens Gamesa’s onshore wind business in India and Sri Lanka, launching the Vayona Energy platform with 12.00 gigawatts of operational and under-development assets. These moves deepen TPG’s exposure to AI infrastructure and renewable energy in fast-growing South Asian markets, reinforcing its focus on long-term thematic...

Live Oak Bancshares recently appointed Ewa M. Stasiowska as Chief Risk Officer of both the holding company and Live Oak Bank, formalizing a dedicated risk leadership function that was previously combined with the General Counsel role. The move comes after Live Oak crossed the US$10.00 billion asset threshold and disclosed plans to restate financial statements for cash flow misclassifications, underscoring a sharper focus on governance and enterprise-wide risk controls. Next, we’ll examine...

Centrilogic has achieved all six designations in the Microsoft AI Cloud Partner Program, highlighting its expertise in delivering comprehensive AI and cloud solutions across Microsoft’s portfolio. This distinction places Centrilogic among a select group of less than 1% of Microsoft's partners worldwide, demonstrating their capability to aid businesses in digital transformation, innovation, and growth. Through these designations, Centrilogic is positioned to support mid-market and enterprise...

Coherent (COHR) just put a brighter spotlight on its stock by unveiling a next generation 300mm silicon carbide platform for AI datacenters, aiming squarely at thermal efficiency and scalability challenges. See our latest analysis for Coherent. That backdrop helps explain why Coherent’s share price is now at $177.35, with a powerful 90 day share price return of 81.27 percent and a three year total shareholder return of 383.24 percent. This signals strong, still building momentum around its AI...

Wondering if Eastman Chemical is a beaten down value play or a value trap at current levels? You are not alone. This article aims to unpack exactly that. With the share price around $60.66 and down 31.5% year to date and 37.8% over the past year, the market has clearly reset its expectations and is forcing investors to rethink the risk reward profile. Recent headlines have focused on Eastman’s strategic push into specialty materials and circular recycling initiatives, alongside ongoing...

Wondering if Innodata is still a smart buy after its massive run, or if most of the upside is already priced in? You are not alone, and that is exactly what we are going to unpack here. The stock is up 47.7% year to date and 31.0% over the last year, but that rides on the back of a huge 1,776.2% three year gain and 1,024.3% over five years, with a recent 1.5% rise in the last week despite a 9.8% pullback over the past month. Markets have been reacting to Innodata as one of the pure play...

Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in? Despite a modest slip of 2.4% over the last week and being roughly flat over 30 days, the stock is still up 10.5% year to date and over the past year, hinting that long term sentiment remains constructive at around $125.40 per share. Recent headlines have focused on Abbott’s continued push in medical devices and diagnostics, alongside regulatory...

Cipher Mining (CIFR) just flipped the script on its business model, locking in multi billion dollar AI and high performance computing data center deals with AWS and Fluidstack that reshape its long term revenue picture. See our latest analysis for Cipher Mining. The market has already been repositioning Cipher around this pivot, with a 1 year to date share price return above 300 percent and a 3 year total shareholder return above 2,300 percent, signaling powerful but volatile momentum. If...

Recent move and performance context 10x Genomics (TXG) has been quietly grinding higher, with the stock up about 36% over the past month and 30% in the past 3 months, after a choppy multi year stretch. See our latest analysis for 10x Genomics. That recent surge sits against a mixed backdrop, with a solid year to date share price return but a still deeply negative three year total shareholder return that shows how long term holders have been tested. This suggests that momentum is rebuilding as...

Methode Electronics (MEI) just posted Q2 2026 results with revenue of $246.9 million and a basic EPS loss of $0.28, as the trailing twelve months show revenue of $984.4 million alongside a basic EPS loss of $1.78. The company has seen quarterly revenue move in a relatively tight band from $292.6 million in Q2 2025 to $246.9 million in Q2 2026, while EPS has stayed in negative territory across the same stretch. This is setting the stage for investors to focus on how long current margin...